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Abstract 
 
Glioma is the most frequent form of malignant brain tumor in the adults and childhood. 
There is a global tendency toward a higher incidence of gliomas in highly developed 
and industrialized countries. Simultaneously obesity is reaching epidemic proportions in 
such developed countries. It has been highly accepted that obesity may play an 
important role in the biology of several types of cancer. We have developed an in vitro 
method for the understanding of the influence of obesity on glioma mouse cells 
(Gl261).  
3T3-L1 mouse pre-adipocytes were induced to the maturity. The conditioned medium 
was harvested and used into the Gl261 cultures. Using two-dimension electrophoresis it 
was analyzed the proteome content of Gl261 in the presence of conditioned medium 
(CGl) and in its absence (NCGl). The differently expressed spots were collected and 
analyzed by means of mass spectroscopy (MALDI-TOF-MS).  
Significantly expression pattern changes were observed in eleven proteins and enzymes. 
RFC1, KIF5C, ANXA2, N-RAP, RACK1 and citrate synthase were overexpressed or 
only present in the CGl. Contrariwise, STI1, hnRNPs and phosphoglycerate kinase 1 
were significantly underexpressed in CGl. Aldose reductase and carbonic anhydrase 
were expressed only in NCGl. 
Our results show that obesity remodels the physiological and metabolic behavior of 
glioma cancer cells. Also, proteins found differently expressed are implicated in several 
signaling pathways that control matrix remodeling, proliferation, progression, migration 
and invasion. In general our results support the idea that obesity may increase glioma 
malignancy, however, some interesting paradox finding were also reported and 
discussed. 
 
Key words: Glioma, Cancer, Adipose tissue, Obesity, Proteomics, 2D, Mass 
spectroscopy  
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Abbreviation Index 
 
2D-PAGE – Two-dimensional polyacrylamide gel electrophoresis 
AKT – also known as Protein Kinase B (PKB) 
ANXA2 – Annexin A2 
ATP – Adenosine triphosphate 
BMI – Body Mass Index 
CGl – Conditioned glioma cells 
CNS – Central Nervous System 
DCM – Dilated cardiomyopathy  
DMEM – Dulbecco´s Modified Eagle´s Medium 
DNA – Deoxyribonucleic acid 
DTT – Dithiothreitol 
ERK – Extracellular signal-regulated kinases 
FBS – Fetal bovine serum 
HCC – Hepatocellular carcinoma  
HIF-1α – Hypoxia inducible factor-1α  
hnRNPs – Heterogeneous nuclear ribonucleoprotein complexes 
HOP – Hsp70-Hsp90 organizing Protein 
HPV – Human papillomavirus 
Hsp – Heat shock proteins 
IAA – Iodoacetamide 
IARC – International Agency for Research into Cancer 
IL – Interleukin 
KIF5C – Kinesin heavy chain isoform 5C 
  
MALDI-TOF-MS – Matrix-assisted laser desorption-ionization time-of-flight mass 
spectrometry 
Mr – Relative molecular masses 
mRNA – Messenger Ribonucleic Acid 
N-RAP – Nebulin-related-anchoring protein 
NADPH – Nicotinamide adenine dinucleotide phosphate-oxidase 
NCGl – Non-conditioned glioma cells 
PCNA – Proliferating Cell Nuclear Antigen 
PGK1 – Phosphoglycerate Kinase 1  
pI – Isoelectric point 
RACK1 – Receptor for activated C kinase 1 
RFC1 – Replication factor C subunit 1 
ROS – Reactive oxygen species 
STI1 – Stress-induced phosphoprotein 1  
TCA – Tricarboxylic acid 
TFA – Trifluoroacetic 
TNF-α – Tumor Necrosis Factor α 
VEGF – Vascular Endothelial Growth Factor 
WAT – White Adipose Tissue 
WCRF – World Cancer Research Fund 
WHO – World Health Organization  
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INTRODUCTION 
 
CENTRAL NERVOUS SYSTEM TUMORS 
 
A central nervous system (CNS) tumor begins when normal cells in the brain or 
the spinal cord change and grow uncontrollably, forming a mass. Several different types 
of tumors, benign and malignant, have been identified in the CNS. They often form in 
different areas, develop from different cell types, and may have a different outlook and 
treatment. The prognoses for these tumors are related to several factors, such as the age 
of the patient, the location and histology of the tumor.  
Brain and spinal cord tumors are different in adults and children. In adults, about 
half of all CNS tumors are malignant, whereas in pediatric patients, more than 75% are 
malignant. Malignant primary brain tumors are the leading cause of death from solid 
tumors in children and the third leading cause of death from cancer in adolescents and 
adults aged 15 to 34 years.  
Common presenting symptoms include headache, seizures, nausea, vomiting, 
neurocognitive symptoms, personality changes and altered mental status. For most 
benign CNS tumors that require treatment, neurosurgeons can offer curative resections 
or at least provide significant relief from mass effect. There are not known 
environmental factors associated with brain tumors however mutations and deletions of 
so-called tumor suppressor genes are thought to be the cause of some forms of CNS 
tumors.  
The lack of effective treatments for most primary and secondary malignant CNS 
tumors is still a reality. However, the past decade has witnessed an explosion in the 
understanding of the early molecular events in malignant primary CNS tumors, and for 
the first time in history, oncologists are seeing that a plethora of new therapies targeting 
these molecular events are being tested in clinical trials. There is hope on the horizon 
for the fight against these deadly tumors (1–3). 
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GLIOMA  
 
 
Glioma is a broad category of brain and spinal cord tumors and it is called a 
glioma because it comes from glial cells. Malignant glioma is the most common 
subtype of brain cancer in the adult and pediatric populations and has been subject of 
increasingly research over the past two decades that led to considerable advances in the 
understanding of their basic biology and pathogenesis (4,5).  
Malignant gliomas are histologically heterogeneous and invasive. A number of 
studies have investigated molecular subclasses in Gliomas. There are different grading 
systems in use, the most common is the World Health Organization (WHO) grading 
system that distinguishes glioma according to their constitutive cells, such as 
astrocytomas (glioblastoma), oligodendroglioma and oligoastrocytoma. The 
astrocytomas can be classified according to histological features in four different grades 
of gliomas based on the pathologic evaluation of the tumor. According to this grading 
system, tumours are graded from I (least advanced disease - best prognosis) to IV (most 
advanced disease - worst prognosis). Low-grade gliomas, WHO grade II, are well-
differentiated (these are not benign but still portend a better prognosis for the patient). 
High-grade, WHO grade III-IV, gliomas are undifferentiated (these are malignant and 
carry a worse prognosis – glioblastoma). Grade I tumors are biologically benign and can 
be cured if they can be surgically resected; grade II tumors are low-grade malignancies 
that may follow long clinical courses, but early diffuse infiltration of the surrounding 
brain renders them incurable by surgery; grade III tumors exhibit increased anaplasia 
and proliferation over grade II tumours and are more rapidly fatal; grade IV tumours 
exhibit more advanced features of malignancy, including vascular proliferation and 
necrosis, and as they are recalcitrant to radio/chemotherapy they are generally lethal 
within 12 month (4,6–8). 
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Prognosis is extremely poor, with a median survival time of approximately 12 to 
15 months and is almost invariably fatal (6). This tumor represents about 12-15% of all 
primary brain tumors and about 60-75% of all astrocytomas. Gliomas increase in 
frequency with age, and affect more men than women. Only 3% of childhood brain 
tumors are glioblastomas (6,8,9). 
Glioblastoma is the primary type brain tumor and is the most common and 
aggressive malignant glioma in humans. Representing up to 50% of all primary brain 
gliomas, accounts for approximately 12-15% of all brain tumors and median survival is 
less than 15 months and overall survival is less than 10% at 5 years. These tumors are 
usually highly malignant, fatal and extremely invasive because of the fast cellular 
reproduction supported by a large network of blood vessels, contributing to the poorer 
prognosis of these patients. Glioblastoma contain so many different types of cells, 
usually penetrates deep into the brain, making the tumor difficult to remove for surgery. 
Some cells may respond well to certain therapies, while others may not be affected at 
all. This is why the treatment plan for glioblastoma may combine several approaches. 
These tumors also can affect parts of the brain that control speech, vision or motor 
functions. Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, 
Figure 1 – World Health Organization (WHO) grading system for histological features. 
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antiangiogenic therapy, surgery and experimental approaches such as gene transfer (9–
12).  
Nowadays, the management of patients with glioblastoma continues to harbor 
significant challenges, and comprehensive genetic screens of tumor tissues and 
signaling pathways have been explored to develop molecular based targeted therapies. 
Expression profiling studies have revealed that molecular classification of gliomas may 
be of significant prognostic value. 
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LINKING OBESITY AND CANCER 
 
In 2001, different studies from the International Agency for Research into 
Cancer (IARC) and the World Cancer Research Fund (WCRF) have reported a 
relationship and established a link between obesity and cancer risk (13,14). Excess 
adiposity is related with an increase the incidence and/or death rates from a wide variety 
of human cancers, being the most commons colon, rectum, esophagus, kidney, 
pancreas, gallbladder, ovary, cervix, liver, prostate and certain hematopoietic cancers 
(13–17). Excess adiposity is related with an increase the incidence and/or death rates 
from a wide variety of human cancers (18,19). It is important to understand the 
pathophysiological mechanisms that play a role in the link between obesity and cancer 
focusing on future preventive and therapeutic strategies for cancer (18).  
 The relationship between the increase and dysfunction of adipose tissue might 
thus be a possible cause of cancer. Obesity and accelerated weight gain, in adults, are 
associated with increasing incidence of all central nervous system tumors, mostly 
glioma. At the present time, it is not clear which factors might be involved in this 
relationship but energy balance during childhood and/or adolescence may play a role in 
the etiology of adult-onset glioma. Genes that influence obesity are highly expressed in 
the brain and could also mediate glioma susceptibility (5,20).  
Adipose tissue is also recognized by its endocrine function as producer of 
biological mediators important to the body’s physiology (18,19). Thus, its dysfunction 
results in altered serum levels of adipokines, and some of these hormones and growth 
factors, secreted by adipocytes, appear to be associated with carcinogenesis (13,18). The 
suggested mechanisms underlying these associations namely include biological 
pathways linking energy balance and cancer risk, should be more closely investigated. 
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OBESITY AS A DISEASE RISK FACTOR  
 
The concept of energy homeostasis consists of the exact equilibrium between 
caloric intake and energy utilization. Energy expenditure takes the form of physical 
activity, which refers to all voluntary movement, basal metabolism which includes the 
biochemical processes necessary in life, and adaptive thermogenesis (15). The 
development of obesity occurs when caloric intake routinely exceeds caloric 
expenditure over a prolonged time leading to the increased body mass including the 
accumulation of subcutaneous and visceral fat, promotes weight gain (15–17). Obesity 
is defined as an abnormal or excessive fat accumulation, this is, an increased storage of 
fatty acids in an expanded adipose tissue mass (15,21). 
During the past several decades, the excess adiposity in the population is an 
unintentional consequence of the economic, social, and technological advances. Foods 
low in cost, abundant and palatable with high caloric density are readily available in 
prepackaged forms and in fast-food restaurants. Labor-saving technologies and 
widespread availability of electronic devices in homes have greatly reduced the amount 
of physical activity that used to be part of daily life and promoted a sedentary life style. 
Considering genetic and environmental factors to the etiology of obesity, studies have 
concluded that about 30% to 40% of the variance in body mass index (BMI) can be 
attributed to the genetics factor and 60% to 70% to the environment. The interaction 
between genetics and environment is also important being that some people already 
genetically predisposed to develop obesity only express this genotype if exposed to 
certain adverse environmental conditions, such as high-fat diets and sedentary lifestyle 
(16,17).  Obesity is a complex disease caused by different factors such as genetic, diet, 
lifestyle and environmental factors (15).  
The World Health Organization (WHO) estimates that worldwide there are 
approximately 1.6 billion individuals aged 15 years and older are overweight (BMI ≥ 25 
kg/m2), 400 million of whom are obese (BMI ≥ 30kg/m2) (13,15). In the United States 
24.2% of men and 23.5% of women were obese in 2005, and 21.9% of men and 24.4% 
of women were obese in the United Kingdom in 2007 (13). 
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Obesity is a major cause of morbidity and mortality and is associated with an 
increased risk for many disorders including hypertension, dyslipidemia, insulin 
resistance and type II diabetes mellitus, atherosclerosis, described altogether as  
metabolic syndrome, as well as different kinds of cancer (13,15–17,21). 
 
 
 
 
Different studies from the International Agency for Research into Cancer 
(IARC) in 2001 and the World Cancer Research Fund (WCRF) have observed a 
relationship and established a link between obesity and cancer risk (13). The risk of 
endometrial cancer and breast cancer after menopause is higher in obese women. 
Excessive adiposity may increase the incidence and/or death rates from a wide variety 
of human cancers, being the most common colon and rectum, esophagus, kidney, 
pancreas, gallbladder, ovary, cervix, liver, prostate, and certain hematopoietic cancers 
(13,15–17).  
Figure 2 – Summary of pathways that may link obesity to cancer development. A convergence 
of increased inflammation, insulin signalling, increased availability of lipids and other 
macromolecules, and changes in adipokine signalling may contribute to the conversion of normal 
epithelial cells to an invasive tumour. Although all of these pathways can contribute to cancer in 
certain circumstances, it remains unclear whether these pathways are predominantly required for 
cancer in obese humans. Adapted from Khandekar et al. 2011. 
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While public health policies aim the reduction of obesity epidemy and 
implementation of strategies for this problem, there is a simultaneous need to better 
understand the biological processes linking obesity and cancer as a precondition to the 
development of new approaches to prevention and treatment (13). 
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ADIPOSE TISSUE – A MAJOR PLAYER IN METABOLISM 
 
In most mammalian, adipose tissue is classified according molecular and 
histological characteristics in white adipose tissue (WAT) and brown adipose tissue. 
The first is most abundant and the second plays an important role in thermogenesis, 
only found in humans during childhood when participating in maintaining body heat. 
The WAT acts as a reserve of energy, states that during caloric deprivation can be 
mobilized by releasing free fatty acids will be oxidized in other tissues and organs. This 
tissue promotes thermal isolation and plays an important role in the regulation of 
glucose homeostasis (22–25). 
 The adipose organ is made up of adipocytes, vascular tissue and immune cells. 
Adipose tissue beyond the adipocytes (most abundant cells) also has several other cell 
types such preadipocytes, stromal cells, fibroblasts, leucocytes and macrophages (22–
27). Adipocytes vesicles have more than 90% of fat occupation of the total cell volume, 
which in addition to functioning as energy deposits also show high amounts lipolytic 
activity releasing free fatty acids into plasma as needed (24).  
Contrary to what was thought for many years, adipose tissue is not just an 
“energy storage” of triglycerides but also an endocrine organ affecting immunological 
processes and metabolism of the body. Adipose tissue secrets a number of bioactive 
mediators referred to as adipocytokines, which may be hormones, enzymes and growth 
factors. Such substances have an auto and paracrynic effect on adipocytes production, 
although they also have an endocrynic effect on other tissues and organs. They regulate 
energy homeostasis within the organism by directing both energy intake and 
expenditure (22–27).  
However, it was only in 1994 with the discovery of leptin, the first hormone 
produced by adipocytes to be identified that led to the acceptance of adipose tissue as an 
endocrine organ (23). After the discovery of leptin several other hormones produced by 
adipocytes were found such as adiponectin, angiotensin, resistin and visfatin and 
addition of various cytokines such as Tumor Necrosis Factor α (TNF α), interleukin 1 
(IL-1), IL-6, IL-8 and growth factors such as Vascular Endothelial Growth Factor 
(VEGF), which participate in inflammation (24–26). Adipose tissues dysfunction results 
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in altered serum levels of adipokines, and some of these hormones and growth factors 
secreted by adipocytes appear to be associated with carcinogenesis (13,18). The 
inflammation, insulin resistance and angiogenesis may be a better qualitative indicator 
of the potential carcinogenesis of obesity (18,19). Angiogenesis is a critical step during 
carcinogenesis and VEGF represents a good biomarker in cancer studies. The major 
causes of therapeutic resistance in glioma cancer it seems to be a formation of abnormal 
tumor vasculature and glioma cells invasion (28,29). 
 
 
  
Figure 3 – Adipose tissue composition. Adipose tissue obesity is a chronic inflammatory 
disease and induces inflammatory cascades, including accumulation of immune cells, activation 
of leukocyte-endothelial interaction, coupled angiogenesis and adipogenesis, and adipocyte cell 
death. Adapted from Nishimura et al. 2011. 
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ADIPOSE TISSUE AS AN ENDOCRINE ORGAN 
 
LEPTIN 
 
Leptin was the first adipokine to be discovered. Leptin is encoded by the ob gene 
and acts at the level of the hypothalamus which regulates energy homeostasis and body 
weight, producing satiety signals, thereby suppressing food intake and stimulating 
energy expenditure. Obese individuals have higher leptin levels. In common forms of 
obesity are observed an increase in leptin levels associated with leptin resistance, 
particularly the impact anorexigenics core, for reasons not yet clarified (18,22–24,30–
32). 
This hormone has several other functions including regulation hematopoietic, 
and angiogenic also acts as a mediator in immune and inflammatory processes.  Leptin 
is a pleiotrophic hormone in relation to the link between obesity and cancer. Being 
mitogenic for various cell types and it is antiapoptotic and proangiogenic in itself, also 
in synergy with vascular endothelial growth factor (VEGF) and a potent 
proinflammatory agent. Leptin belongs to the family of adipokines since the molecular 
structure is homologous to the family of cytokines (13,18,23,24,26,30). 
 
ADIPONECTIN 
 
Adiponectin is the most abundant adipokine and is exclusively produced in the 
adipose tissue. Is a polypeptide hormone with a molecular weight 30kDa consisting of 
244 amino acids containing an amine group (N) following signal terminal. Adiponectin 
is found in plasma in two forms, long form (t-adiponectin) and short form or globular 
fragment (g-adiponectin) (13,18,30–32). 
Adiponectin works differently from the other adipokines in almost all of its 
biological properties and effects. This hormone plays an important role in the regulation 
of energy balance and glucose homeostasis, working as antidiabetic, anti-inflammatory, 
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antiatherogenic, proapoptotic and antiangiogenic, by increasing insulin sensitivity.  
Adiponectin provides indirect protection against carcinogenesis. The levels of plasma 
adiponectin are decreased in some pathological conditions such as obesity, insulin 
resistance and cancer (13,18,23,26,30–32). 
 
RESISTIN 
 
Resistin is a protein composed of 114 amino acids, with 12.5 kDa being encoded 
by the gene RETN. The hormone is synthesized by adipocytes, in mice, and in 
adipocytes, myocytes, particularly in pancreatic cells and mononuclear cells 
(macrophages) in humans. The plasma levels are highly correlated with the adipose 
tissue mass (26,30,31). 
 Several studies have shown that levels of resistin are increased in obesity in 
humans and rodents. Like other adipokines, resistin plays a significant role in energy 
homeostasis, for thermogenesis and insulin resistance. The human resistin appears 
functions to perform pro-inflammatory since it promotes the synthesis of pro-
inflammatory cytokines such as TNF, IL-1, IL-6 and IL-12 (30,31). 
 
INTERLEUKIN 6 
 
Adipose tissue is the primary site of production of Interleukin 6 (IL-6), cytokine 
which can directly cause inflammation (21,26,30,32). The plasma concentration of IL-6 
correlates positively with the amount of adipose tissue, obesity and insulin resistance, 
while it is inversely related to insulin sensitivity (21,31,32). 
Participates in immune regulation, the regulation of cellular functions such as 
proliferation, apoptosis, angiogenesis and cell differentiation, acts as a regulator of lipid 
and protein metabolism in adipose tissue and modulates the hypothalamic-pituitary-
adrenal (18,21,30). 
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TNF-α 
 
The tumor necrosis factor α (TNF-α) is a pro-inflammatory cytokine which has been 
described with capacity to promote tumor necrosis. This factor is produced by adipose 
tissue, mostly by resident macrophages. This factor is secreted by monocytes and 
macrophages by binding to receptors on neutrophils promoting response chemotactic. 
TNF-α is also expressed in adipocytes of adipose tissue, predominantly in subcutaneous 
adipose tissue and is related to the mass total fat. Circulating levels of this factor are 
increased in obesity and decrease significantly after weight loss. 
 
VEGF AND ANGIOGENESIS 
 
The vascular endothelial growth factor (VEGF) is a mediator that has molecular 
weight of 46 kDa and their plasma concentrations are positively correlated with the 
amount of visceral adipose tissue (33). Also performs functions mitogenic stimulating 
cell migration, angiogenesis and vascular permeability. It has been shown that VEGF 
plays an important role in vascularization of malignant solid tumors facilitating cell 
invasion and the formation of distant metastases (18,33). 
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Figure 4 – Changes in adipose tissue in obesity. In the obese state, there is an increase in the size 
and number of adipocytes, as well as increases in the inflammatory and endothelial compartments 
of the stromal-vascular fraction. The release of most adipokines is elevated in the state of obesity. 
This is also true for the metabolically beneficial hormone leptin. However, leptin signaling is 
concomitantly impaired, making it an unattractive target for the treatment of obesity. One 
exception from generally elevated adipokine levels is adiponectin, whose secretion is diminished in 
obesity. Inflammatory cytokines (IL-6 and TNFα, are highly upregulated in adipose tissue of obese 
subjects. Adapted from Khandekar et al. 2011. 
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PROTEOMICS 
 
Proteomics is a large-scale comprehensive study of a specific proteome, 
including information on protein abundances, their variations and modifications, along 
with their interacting partners and networks, in order to understand cellular processes. 
The greatest promise for the detection and treatment of cancer lies in the deep 
understanding of molecular basis for disease initiation, progression and efficacious 
treatment based on the discovery of unique biomarkers. Although progress in cancer 
genomics has been rapid during the past few years, it only provides us with a glimpse of 
what may occur as dictated by the genetic code. In reality, we still need to measure what 
is happening in a patient in real time, which means finding tell-tale proteins that provide 
insight into the biological processes of cancer development. This is because genes are 
only the "recipes" of the cell, while the proteins encoded by the genes are ultimately the 
functional players that drive both normal and disease physiology (7,34,35).  
 
POTENTIAL BENEFIT OF GLIOMA PROTEOMICS  
 
The accessibility of cancer-related proteins in malignant glioma has triggered 
extensive protein-focused research for the hunt of biomarkers. In addition to the urgent 
need for novel efficient drug targets against malignant gliomas, the identification of 
glioma biomarkers will provide a much needed contribution to diagnosis, treatment 
decision, prognosis and assessment of treatment response. Current diagnosis is based on 
classical histopathological examination, a challenging task considering the 
heterogeneity of the disease and the inherent subjective nature of histopathological 
grading. Proteomics has the ability to interrogate a variety of biospecimens for their 
protein contents and accurately measure the concentrations of these proteins. This can 
provide scientists and clinicians with a powerful tool to understand the different 
processes involved in cancer development and progression in hope to identify 
biomarkers specific for these cellular processes along with those indicating efficacious 
therapeutic intervention (7,34,35).  
Proteomic analysis of the influence of the adipocyte secretome on glioma Gl261 cells 
 
  
Página 17 
 
  
OBJECTIVES 
 
The present study, aims to develop an in vitro rodent model for the study of the 
influence of obesity role in glioma. We propose a model in which cell line GL261 a 
mouse glioma is cultured in the presence or absence of a conditioned medium of 3T3-
L1 mature adipocytes. The 3T3-L1 pre-adipocytes were differentiated under controlled 
experiments. We have used the mature adipocytes secreted adipokines (secretome) and 
enriched the GL261 medium, followed by analysis of the proteins on GL261 on a 2-
dimensional proteomic gel approach, so different spots could be studied by means of 
mass spectroscopy. The major findings will be explored in the present work. 
 
Specific objectives  
 Preparing 3T3-L1 conditioned medium on Gl-261 growth. 
 Perform bidimensional electrophoresis (2D) in the whole Gl-261 cell protein 
content with and without 3T3-L1 conditioned medium. 
 Analysis of the 2D gels. 
 Understand the differences between the glioma cells Gl-261 under the effect of 
the conditioned medium in relation to those who grown without that influence. 
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MATERIALS AND METHODS 
 
CHEMICALS 
 
The reagents acetonitrile, iodoacetamide (IAA), dl-dithiothreitol (DTT) (99% 
w/w) and trypsin from porcine pancreas (proteomics grade) were purchased from Sigma 
(Steinheim, Germany). Formic acid puriss for mass spectrometry (≥98%), ammonium 
bicarbonate (>99.5% w/w) and the matrix assisted laser desorption ionization MALDI 
matrix α-Cyano-4-hydroxycinnamic acid (α-CHCA) puriss for MALDI-MS were from 
Fluka (Buchs, Switzerland). Trifluoroacetic acid (TFA, 99% v/v) was from Riedel-de-
Haën (Seelze, Germany). ProteoMass Peptide MALDI-MS Calibration Kit (MSCAL2) 
from Sigma was used as mass calibration standard for MALDI-TOF-MS. 
 
CELL CULTURE 
 
For the current work it were used the mouse cell lines 3T3-L1 (purchased from 
American Type Culture Collection) and GL-261 (gently given by Prof. Pedroso Lima, 
CNC, Coimbra, Portugal). 
The Mouse pre-adipocyte cell line 3T3-L1 and glioma cell line GL-261 were 
cultured in DMEM (Dulbecco´s Modified Eagle´s Medium with 4.5g/L Glucose & L-
Glutamine, without Sodium Pyruvate. Santa Cruz Biotechnology, Inc.), supplemented 
with 10% FBS (Fetal bovine serum), and 1000 units/mL gentamycin solution, 
maintained in T-25 tissue culture flasks in 5% CO2/95% air at 37
o
C in a humidified 
incubator.  
 
  
Proteomic analysis of the influence of the adipocyte secretome on glioma Gl261 cells 
 
  
Página 20 
 
  
ADIPOCYTE DIFFERENTIATION AND CONDITIONED MEDIUM 
COLLECTION 
 
3T3-L1 pre-adipocytes were propagated and allowed to reach confluence. After 
2 days (day 0), the differentiation was initiated by addition of a hormonal mixture 
composed of 2 μM insulin, 1 μM dexamethasone and 0.25 mM isobutylmethylxanthine. 
Three days later (day 3), the induction medium was replaced by complete medium 
supplemented with insulin only. At day 6 cultures were washed twice in phosphate 
buffered saline and incubated in serum-free medium. After 24h (day 7), medium was 
harvested from the adipocytes cultures, spun for 3000 g for 5 minutes and the 
supernatant (mature adipocytes conditioned medium) was stored at -80ºC for the 
subsequent treatments. 
Afterwards, glioma cells were divided in two distinct groups. On one hand, 
glioma cells GL-261 were grown under the influence of the mature adipocytes 
secretome were designated conditioned glioma cells (CGl). On the other hand, the 
control group was designated as non-conditioned glioma cells (NCGl). 
 
SAMPLE PREPARATION FOR 2D-PAGE 
 
Sample preparation for 2D-PAGE was performed according to published 
procedures with minor modifications (36). The cells were manual detached from the 
flask and were mechanically lysed at 4
o
C in lysis solution [CHAPS 4%, 5 mM Tris, pH 
8.8, 0.05% protease inhibitor cocktail (Sigma)] using a glass potter, and  the samples 
were centrifuged at 2000 g for 15 minutes at 4
o
C in order to eliminate aggregates. The 
protein concentrations in each sample were measured by means of a DC Bio-Rad assay. 
A total of 900 mg of protein from each sample was precipitated with cold acetone and 
resuspended in thiourea buffer (7M urea, 2M thiourea 2% CHAPS, 2% ASB14, 5% 
glycerol, 40 mM DTT, 4 mM TCEP, 1% 3–10 IPG buffer, Amersham), and the samples 
were mixed overnight at 4
o
C in the dark and clarified by centrifugation at 16000 g for 
15 minutes at 4
o
C. The supernatant was first separated by isoelectric focusing over a pH 
range of 3–10 using precast first-dimension drystrip 3–10 NL 11 cm (Bio-Rad) 
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following a multi-step protocol for 90,000 Vht (Protean IEF cell, Biorad). The first 
dimension strip was equilibrated in 50 mM Tris, pH 8.8, 6 M urea, 30% glycerol, 2% 
SDS plus 16 mM DTT for 20 minutes, and then plus 25 mM iodioacetamide for 15 
minutes, and loaded on a midi format (11 cm) 9–16% acrylamide gel to separate the 
proteins by molecular weight. Second-dimension runs were performed using Biorad 
midi cells at 30 V 1 h, 300 V 4 h at a constant temperature of 18
o
C. Protein spots were 
revealed using home-made blue Coomassie staining, and the gel images were acquired 
by means of an Image scanner at 300 DPI resolution and analyzed using Image2D 
Master Platinum software (both from Amersham).  
At least three gels per condition were included in the analysis. Normalized spot 
volume values were studied using SPSS software version 13.0 for statistical analysis 
(SPSS Inc.). In brief, the data for each spot match set were analyzed using a box-plot 
test in order to eliminate outliers, a K-S test to check normal distribution, an F test to 
analyze the variance, and finally Student’s t test to compare the mean values, which 
were considered significant when p 0.01. 
 
IN-GEL PROTEIN DIGESTION 
 
In-gel digestion of the excised proteins with trypsin was performed according to 
published procedures with minor modifications (37–39). Protein spots were destained 
for 10 min with a solution of acetonitrile 50% (v/v) in 25nM NH4HCO3 and mixed 
vigorously using a vortex. After removal of the destaining solution, gel pieces were 
washed with water (100 µL) for 10 min using vigorous vortexing. This step was 
repeated twice. Afterwards, the gel pieces were dehydrated in acetonitrile (100 µL) for 
10 min, which was then removed and the gel pieces were placed to dry in a vacuum 
centrifuge. Reduction of protein disulfide bonds was performed with a solution 10mM 
of dithiotreitol (DTT) in 25mM NH4HCO3 (25µL), for 15 min at 60 ºC. After cooling to 
room temperature for about 15 min, the DTT solution was replaced with a solution 
110mM of iodoacetamide (IAA) in 25mM NH4HCO3 (20µL). Incubation with the 
alkylation agent was performed for 35 min at room temperature in the dark. After 
reduction and alkylation steps, the gel pieces were submitted once more to the washing 
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and dehydration procedure with water and acetonitrile, in the same way as described 
above. Subsequently, the gel pieces were completely dried in a vacuum centrifuge. The 
dried protein spots were incubated with a solution of trypsin 25 ng/µL in 12.5 mM 
NH4HCO3 (15µL) in an ice bath for 30 min to rehydrate the gel and to allow enzyme 
penetration into it. In-gel protein digestion was performed at 37ºC overnight. After 
collecting the supernatant to clean vials, further peptide extraction was performed by 
addiction of a solution of trifluoroacetic acid 0.1% (v/v) in acetonitrile 50% (v/v) (25 
µL) to the gel pieces and incubation at room temperature with shaking for 10 min. This 
step was repeated twice. All extracts were pooled and evaporated to dryness. The 
samples were re-suspended with 10 µL of trifluoroacetic acid 0.1% (v/v). 
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MALDI-TOF-MS ANALYSIS 
 
Prior to MALDI analysis, the sample was mixed with an equal volume of the 
MALDI matrix solution, 10 mg/ml α–CHCA in trifluoroacetic acid 0.1% (v/v) and 
acetonitrile 50% (v/v). An aliquot of the sample/matrix solution (0.5 µL) was hand-
spotted onto the MALDI sample plate and the sample was allowed to dry. The mass 
spectrometric analyses were performed using the Applied Biosystems MALDI-TOF-
MS system model Voyager-DE PRO Biospectrometry Workstation equipped with a 
nitrogen laser radiating at 337 nm (Applied Biosystems, Foster City, USA) and the laser 
intensity was set just above the threshold for ion production. MALDI mass spectra were 
acquired in positive ion reflectron mode, with an accelerating voltage of 20 kV, a grid 
voltage of 15 kV, 0.4 V of guide wire and an ion extraction delay of 100 ns. The MS 
spectra for each sample were based on the average of 700 laser shots per spot with an 
acquisition rate of 2 ns. MS acquisition data was calibrated externally using the 
ProteoMass Peptide MALDI-MS Calibration Kit. 
 
DATA ANALYSIS AND DATABASE SEARCHING 
 
All data were processed using DataExplorer 4.5 software from Applied 
Biosystems. Peptide Mass Fingerprint (PMF) data were used to search for candidate 
proteins using the MASCOT database search (http://www.matrixscience.com) engine. 
SwissProt database was selected by default for all Mascot searches. NCBInr database 
was used each time no significant identification was obtained with SwissProt. Database 
searches were, by default, performed with no taxonomy restriction and allowing up to a 
maximum peptide mass tolerance of 100 ppm. The number of allowed missed cleavages 
for trypsin was set to one. Carbamidomethylation of cysteine and methionine oxidation 
were selected as fixed and variable modifications, respectively. In order to provide 
accurate results, protein identification was considered positive for MASCOT protein 
scores higher than 77 (p<0.01) that present a sequence coverage higher than 20% and a 
minimum of 4 peptides matching.  
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RESULTS 
 
In order to understand which proteins are potentially involved in glioma tumor, 
we analyzed the protein expression from glioma cells, with and without conditioned 
medium, by means of bidimensional polyacrylamide gel electrophoresis under 
denatured conditions (2D-PAGE) followed by mass spectrometry analysis of the 
selected spots. These spots were analyzed by matrix assisted laser desorption ionization 
time-of-flight/mass spectrometry (MALDI-TOF-MS). The non-conditioned glioma cells 
(NCGl) were used as the control group for the conditioned glioma cells (CGl).   
 
ANALYSIS OF DIFFERENTIALLY EXPRESSED PROTEINS 
 
After 2D-PAGE, images were analyzed using Image2D Master Platinum 
software (Amersham). Among 1192 matched protein spots, 5 spots were significantly 
over-expressed in CGl (CGl/NCGl ≥ 2, p≤ 0.01), 3 spots were under-expressed in the 
CGl (CGl/NCGl ≤ 0.5, p≤ 0.01), 2 spots only present in NCGl control group and 1 spot 
only present in the CGl (Table 1). 
 
 
 
 
 
 
 
 
 
 
1 
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Figure 5 – Images 1, 2 and 3 are 2D gels from the non-conditioned glioma cells 
(NCGl). 
3 
2 
4 
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Figure 6 – Images 4, 5 and 6 are 2D gels from the conditioned glioma 
cells (CGl).   
5 
6 
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IDENTIFICATION OF DIFFERENTIALLY EXPRESSED PROTEINS 
 
Eleven differentially expressed spots were identified and its detailed information 
is presented in Table 1.  
 There are 5 over-expressed proteins presented as 5 spots on the CG1. RFC1 
corresponds to spot-1 with 9.38 isoelectric point, 126705 relative molecular mass and 
presenting a 2.32 ratio. KIF5C corresponds to spot-2, with 5.86 isoelectric point, 
109777 relative molecular mass and 2.91 ratio. ANXA2 corresponds to a spot-3 protein 
spot, with 7.55 isoelectric point, 38937 relative molecular mass and 2.23 ratio. NRAP, 
corresponds to spot-4, with 9.34 isoelectric point, 196716 relative molecular mass and 
2.82 ratio. RACK 1, corresponds to spot-5, with 7.60 isoelectric point, 35511 relative 
molecular mass and 2.07 ratio (Table 1).  
The 3 spots significantly under-expressed in CGl corresponding to 3 proteins 
identified proteins: STI1, corresponds to spot-6 and it presents a 6.4 isoelectric point, 
63170 relative molecular mass and 0.33 ratio; hnRNP L, corresponds to spot-7 spot, 
with 8.33 isoelectric point, 64550 relative molecular mass and 0.66 ratio; PGK1, 
corresponding to spot-8, with 8.02 isoelectric point, 44921 relative molecular mass and 
0.4 ratio.  
Only 2 spots were present in NCGl control group were aldose reductase, 
corresponds to spot-9, with 6.71 isoelectric point, 36052 relative molecular mass, and 
carbonic anhydrase, corresponds to spot-10, with 6.45 isoelectric point, 30124 relative 
molecular mass. 
The only spot present in the CGl was Citrate Synthase that corresponds to spot-
11, with 8.72 isoelectric point and 51988 of relative molecular mass. 
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Table 1 – Protein identification results retrieved for MALDI-TOF-MS/PMF queries in Mascot database search engine. 
 
Protein 
spot 
Mascot 
MOWSE 
score 1 
Expectation 
value 2 
Database 
N matches (n 
queries) 
% sequence 
coverage3 
pI4 Mr5 Ratio6 Protein ID Abreviation 
Spot-17 69 2.3e-03 Swissprot 14 (43) 14 9.38 126705 2.32 (↑) Replication factor C subunit RFC1 
Spot-2 80 4.9e-03 Swissprot 25 (122) 25 5.86 109777 2.91 (↑) Kinesin heavy chain isoform 5C KIF5C 
Spot-3 102 3.4e-05 Swissprot 20 (107) 52 7.55 38937 2.23 (↑) Annexin A2 ANXA2 
Spot-4 90 5.2e-04 Swissprot 37 (109) 24 9.34 196716 2.82 (↑) Nebulin-related-anchoring protein NRAP 
Spot-5 125 1.7e-07 Swissprot 14 (67) 53 7.60 35511 2.07 (↑) 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 
RACK1 
Spot-6 100 5.8e-05 Swissprot 18 (68) 35 6.40 63170 0.33 (↓) Stress-induced phosphoprotein 1 STI1 
Spot-7 93 2.7e-04 Swissprot 17 (65) 35 8.33 64550 0.66 (↓) 
Heterogeneous nuclear 
ribonucleoprotein L 
hnRNP L 
Spot-8 93 2.9e-04 Swissprot 21 (128) 61 8.02 44921 0.4 (↓) Phosphoglycerate Kinase 1 PGK1 
Spot-9 110 5.4e-06 Swissprot 14 (72) 48 6.71 36052 Only in NCGl Aldose reductase - 
Spot-108 79 7.1e-03 Swissprot 10 (54) 40 6.45 30124 Only in NCGl Carbonic anhydrase - 
Spot-117 64 6.0e-03 Swissprot 8 (58) 17 8.72 51988 Only in CGl Citrate synthase, mitochondrial - 
 
1
 scores greater than 77 are significant for p<0.01 
2
 number of matches with equal or better scores that are expected to occur by chance alone 
3
 represents the percentage of the protein's sequence represented by the peptides identified in the MS run 
4 
isoelectric point 
5
 relative molecular masses  
6
 Ratio = CGl/NCGl (CGl – conditioned glioma cells, NCGl – non-conditioned glioma cells) 
7 
Obtained by limiting the research to entries from Mus musculus. In this case, scores greater than 62 are significant for p<0.01. 
8
 Obtained allowing up to 2 missed cleavages 
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DISCUSSION 
 
High grade gliomas are the most common and malignant brain tumors in adults 
and their morbility and mortality nature makes them the fourth major cause of cancer 
death. It is crucial to invest in neuro-oncology research to find new glioma biomarkers, 
to grade specific protein signatures to provide treatment efficacy, and to identify novel 
effective drug targets against malignant glioma (7). 
The proteomic analyzes of the current work has allowed the identification of 
eleven well differentiated proteins whose molecular role on cell and cancer biology will 
be discussed in the following text. 
 
UNDER-EXPRESSED PROTEINS 
 
Stress-induced phosphoprotein 1 (STI1), also known as HOP (an abbreviation 
for Hsp70-Hsp90 organizing Protein), is a co-chaperone which mediates the association 
of the molecular chaperones Hsp70 (an abbreviation for heat shock proteins 70) and 
Hsp90 and can be found in diverse cellular locations. STI1 belongs to the large group of 
co-chaperones which brings and holds together Hsp70 and Hsp90 but also modulates 
the activities of these major chaperones (40). In addition to its role in the Hsp70/Hsp90 
protein folding system it seems to participate in several other cellular processes 
including transcription, protein translocation, viral replication, signal transduction, and 
cell division (40–42). It has been reported that STI1 is secreted by different types of 
cancers such as hepatocellular carcinoma (HCC), ovarian cancer, pancreatic cancer and 
glioblastoma, being able to promote tumor cell proliferation and invasion (34,35,41,42). 
In neuronal cells it was revealed that STI1 is produced by normal astrocytes (43). 
However, and according to Erlich et al. STI1 is expressed by a glioblastoma cell line 
(A172), promotes proliferation of distinct glioma cell lines and mediates the ERK 
(Extracellular signal-regulated kinases) and AKT (also known as Protein Kinase B-
PKB) signaling pathways, induce proliferation and conversely does not induced 
proliferation of normal astrocytes (42).   
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Heterogeneous nuclear ribonucleoprotein complexes (hnRNPs) is a family of 
proteins that plays a central role in the RNA metabolism as formation, packaging, 
processing, splicing and function of mRNA in the cytoplasm (44–46). Proteins of this 
complex are termed A1 to U and many hnRNPs genes may be regulated by oncogenes 
(46). hnRNPL is present in the nucleoplasm as part of the hnRNPs but has also been 
identified outside of the nucleoplasm (44,46). The hnRNP proteins are aberrantly 
expressed in cancer cells supportting the theory that they are implicated in tumor 
development. HnRNP L has been shown to regulate the expression of VEGF under 
hypoxic conditions. It also binds a specific base region of VEGF mRNA and increase 
VEGF protein production, only in cells under hypoxic stress. This interesting 
association protein-VEGF mRNA suggest that hnRNP L plays an important role in 
angiogenesis and tumorigenesis (44,46).   
Figure 7 – Possible mechanism that suggests that STI1 promotes proliferation of distinct 
glioma cell by ERK and AKT signaling pathway. 
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Phosphoglycerate Kinase 1 (PGK1) is an enzyme that catalyzes a reversible 
chemical reaction that converts 1,3-disphosphoglycerate to 3-phosphoglycerate, 
producing one molecule of adenosine triphosphate (ATP) during the breakdown of 
glucose. PGK1 overexpression has been associated with gastric cancer, lung 
adenocarcinoma, prostate cancer, pancreatic tumor, breast cancer, multidrug resistant 
cancer and astrocytoma radioresistance (47–51). Researchers suspect that PGK1 is 
involved in many pathophysiological mechanisms like radioresistance, tumorigenesis, 
DNA replication and repair and angiogenic processes (49,51,52).  
 
Our findings revealed lower expression of STI1 (0.33 fold), hnRNP L (0.66 fold) 
and PGK1 (0.4 fold) when glioma cells were exposed to mature adipocytes conditioned 
medium. Regarding multiple effects of STI1, this under-expression might reflect that 
the adipokines secreted by mature adipocytes might be able to stop some important 
pathways in carcinogenesis. In what concerns to PGK1 it may be under-expressed on 
the glioma cells under conditioned medium due to a mechanism of remodeling the 
oxidative metabolism toward the utilization of fatty acids substrates instead of glucose. 
This interpretation may be supported by the increased expression of mitochondrial 
citrate synthase.   
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SUPPRESSED PROTEINS  
 
Two enzymes were suppressed on the glioma cells cultured with conditioned 
medium. 
Aldose reductase is an enzyme that belongs to aldo-keto reductase superfamily 
and reduces glucose to sorbitol in the presence of NADPH, the first step in polyol 
pathway of glucose metabolism. The second and last step in the polyol pathway is 
catalyzed by sorbitol dehydrogenase, which catalyzes the NAD-linked oxidation of 
sorbitol to fructose. Thus, the polyol pathway results in conversion of glucose to 
fructose with use of NADPH and production of NADH (53). Recently, the potential 
physiological role of aldose reductase has been reassessed from a different perspective. 
Recent studies suggested that aldose reductase, besides reducing glucose, also 
efficiently catalyzes the reduction of reactive oxygen species (ROS), lipid peroxidation 
generating lipid aldehydes and their glutathione conjugates. The elevated levels of ROS 
with high chemical reactivity cause lipid peroxidation and oxidation of proteins and 
nucleic acids, which can increase the risk of mutagenesis. Aldose reductase is activated 
and overexpressed under conditions of oxidative stress and inflammation. This protein 
is a regulator of ROS signals induced by activation of transcription factors such as NF-
κB and AP1. It has been shown that aldose reductase can be one of the main mediators 
of inflammatory signals and proliferation of cancer cells. Indeed, a large number of 
recent studies point that aldose reductase inhibition prevents oxidative stress-induced 
activation of NF-κB and AP1 signals and, consequently, inflammatory complications of 
cancer (53,54).  
 
Carbonic anhydrase is a family of enzymes that participate in a variety of 
biological processes, including respiration, calcification and acid-base balance, because 
they catalyze the reversible hydration of carbon dioxide. It is one of the transcription 
products of hypoxia inducible factor-1α (HIF-1α) and is over-expressed in hypoxic solid 
tumors. Carbonic anhydrase plays an important role in tumorigenesis and drug 
resistance because regulates many pathways including angiogenesis, glycolysis, growth 
factor signaling, apoptosis, genetic instability, metastasis and tissue invasion. Carbonic 
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anhydrase is identified as to be one of the best cellular biomarkers of hypoxia. 
Furthermore, some recent studies are exploring the association between carbonic 
anhydrase levels and the capacity to induce resistance to cytotoxic therapy (55).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Our research revealed that aldose reductase and carbonic anhydrase were present 
only in glioma cells and that their expression was completely blocked when glioma cells 
were exposed to mature adipocytes conditioned medium. Our findings suggested that 
this blockage may reflect a total inhibition of aldose reductase and carbonic anhydrase, 
possibly associated to oxidative stress response prevention, inhibition of inflammation 
and cancer proliferation, drug resistance, angiogenesis and carcinogenesis, which may 
suggests some kind of protective mechanism related to obesity.   
Figure 8 – At normal oxygen levels (normoxia) hypoxia inducible factor-alpha (HIFalpha). is 
degraded by the ubiquitin–proteasome system. Under hypoxia, carbonic anhydrase is one of 
the transcription products of HIF-1α. 
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OVER-EXPRESSED PROTEINS 
 
Replication factor C subunit 1 (RFC1) participates in eukaryotic replication as a 
clamp loader. Its role as clamp loader involves catalysing the loading of Proliferating 
Cell Nuclear Antigen (PCNA) on to DNA, encircles DNA in a ring. It binds to the 5' 
end of the DNA and spends ATP to open the ring of PCNA so that it can encircle the 
DNA. ATP hydrolysis releases the PCNA-DNA complex, with concomitant clamp 
loading onto DNA (56–58). RFC1 also plays an important role in maintaining the 
stability and the integrity of the genome and by coping with various genomic stresses as 
well. This mechanism is a DNA repair pathway and prevents fatal genomic 
rearrangements. Genome instability is a hallmark of cancer cells and plays a critical role 
in generating the variability that allows cancer cells to evolve during tumor progression 
(59). Considering RFC1 over-expression by a 2.32 fold in glioma cells cultured with 
conditioned medium, RFC1 may be involved in protector reparative mechanisms under 
obesity environment. 
 
Kinesin heavy chain isoform 5C (KIF5C) is a novel kinesin motor protein, firstly 
thought to be expressed exclusively in neurons, preferentially in motor neurons. This 
motor kinesin is also linked to synaptic vesicle components in neuronal cells where it 
plays a role in anterograde trafficking of mitochondria and vesicles. In the absence of 
this protein, KIF5C knockdown mice revealed a decrease in brain mass (60). Chicken 
embryos studies unveiled functional KIF5C in non-neuronal tissues, however, has not 
yet been described it’s complete function. More recently KIFC5 has been involved in 
apical protein transport of polarized MDCK (canine) cells. It is important to mention 
that KIF5C phosphorylation plays a key role in the regulation of these motor proteins 
because pharmacological treatment of kinases and phosphatases results in altered 
vesicle motility (61). Moreover, a link has been established between APC tumor 
suppressor protein and KIF5C with overlapping distributions along microtubules 
segments, as well as in cell periphery (62). Since KIF5C is over-expressed in glioma 
under condition conditioned medium it may suggests that obesity may play some role 
on proliferation and axonal transport on cancer cells. 
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Annexin A2 (ANXA2), a member of the annexin family, is a calcium-dependent 
phospholipid-binding intracellular protein found on various cell types. ANXA 2 
heterotetramer consists of two subunits of ANXA2 and two subunits of p11 (member of 
S100 family). ANXA 2 is involved in a diverse range of physiological cellular 
processes. ANXA 2 has anti-inflammatory and anticoagulation role and is also involved 
in endocytosis and exocytosis, signal transduction, cell proliferation, differentiation and 
apoptosis. Increased ANXA2 expression results in increased plasmin generation and 
enhances cancer invasion and metastasis (63,64). On the cell surface (ANXA2) binds to 
t-PA and activates plasminogen conversion to plasmin. ANXA2 is over-expressed in 
hepatocellular carcinoma, colorectal cancer, breast cancer, ovarian cancer, pancreatic 
cancer, acute promyelocytic leukemia, renal cell carcinoma and glioma when activated 
the tPA/plasminogen proteolytic system. In glioma, ANXA2 play a central role in cell 
motility, migration, invasion and angiogenesis (63–65). On the other hand, it is under-
expressed in prostate cancer, esophageal squamous carcinoma and nasopharyngeal 
carcinoma and sinonasal adenocarcinoma (63,64). Our analysis revealed that ANXA2 
expression (2.23 fold) was more pronounced when glioma cells were exposed to 
adipocytes conditioned medium. This finding is in agreement with previous studies that 
also revealed that ANXA2 is elevated in glioma (63–65).  
 
 
 
 
 
 
 
 
 
 
 Figure 9 – Proposed mechanism of annexin A2 promoting cancer metastasis in the plasminogen 
activation system. Increased annexin A2 expression results in increased plasmin generation and 
enhances cancer invasion and metastasis. From Lokman N et al. 2011. 
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Nebulin family is known for some different cellular functions namely in 
cytoskeletal stability, cell migration, as well as protein scaffolding (66). Nebulin-
related-anchoring protein (N-RAP), one of nebulin family members, is highly over-
expressed in animal models of dilated cardiomyopathy (DCM), which exhibited an 
early increase in N-RAP expression before the manifestation of DCM. Authors 
suggested that it could be an adaptive response to strengthen the link between the 
myofibrils and the membrane at intercalated discs (66). Furthermore, it has been found 
over-expressed in human pancreatic cancer. Wu et al. have associated N-RAP with loss 
of heterozygosity (LOH) in glioblastoma (67). Thus, our protein expression of 2.82 fold 
can be related to a cellular mobilization and reorganization typical in a tumor 
microenvironment. 
 
Receptor for activated C kinase 1 (RACK1) is a highly conserved intracellular 
adapter protein in multiple intracellular signal-transduction pathways. RACK1 
integrates inputs from distinct signaling pathways, being critical for fundamental 
cellular activities such as cell proliferation, migration, adhesion and spreading, 
transcription and protein synthesis, as well as many neuronal functions (68). Many 
reports indicate that RACK1 plays an important role in cancer progression and that it is 
over-expressed during angiogenesis and in many human carcinomas (69). RACK1 is 
over-expressed in hepatocellular carcinoma, colon cancer and metastic melanoma (70–
72). RACK1 is also implicated as a key player in ovarian cancer (73), prostate cancer 
(74) and in cancers caused by pathogens such as human papillomavirus 16 (HPV 16) 
(75) and Helicobacter pylori (76). The focal adhesion kinase/RACK1 complex is 
needed for cell spreading, polarity and chemotactic invasion affecting spreading 
initiation and cancer cell polarity (77). Specifically, RACK1 expression is being 
assessed as a biomarker and a prognostic indicator in breast cancer (78). In pulmonary 
adenocarcinomas, increased RACK1 expression is associated with pathological stage 
and tumor size and is also a potential diagnostic biomarker (79). In our assays, glioma 
cells exposed to adipocytes conditioned medium increases RACK1 expression by 2.07 
fold. Given the potential deleterious effect of up regulated RACK1 expression in several 
tumors, which may be related with a less favorable prognosis, we might assume the 
potential use of this protein as a potential biomarker to the glioma invasiveness and/or 
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prognosis determination. 
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CITRATE SYNTHASE WAS PRESENT ONLY THE CGL 
 
Citrate synthase is a mitochondrial enzyme that exists in nearly all living cells 
and catalyzes the first reaction of the tricarboxylic acid (TCA) cycle -the condensation 
of acetyl-CoA with oxaloacetate to yield citrate- which regulates energy generation in 
mitochondrial respiration, and is generally assumed to be the rate-limiting enzyme of 
the cycle (80). Cancer-associated alterations in metabolism are no longer viewed as an 
indirect response to cell proliferation and survival signals (81). The ‘Warburg effect’ 
and metabolic reprogramming has attained the status of a hallmark of cancer (81,82) 
and citrate seems to play a central role in the metabolism of cancer cells (83). Low 
levels of citrate and the loss of citrate synthase is associated with the so-called aerobic 
glycolysis, as well as with malignancy in cervical cancer (84). The growth of various 
human cancer cells stopped when cultured with citrate (83,85,86). Citrate can also 
sensitize cancer cells to chemotherapy (86). Conversely, an enhanced citrate synthase 
activity has also been reported in human pancreatic cancer (87). Our findings revealed 
that citrate synthase expression was only found when glioma cells were treated with 
adipocytes secretome. According to previous studies, metabolic patterns of most cancer 
cells rely on the aerobic glycolysis. This increase in citrate synthase expression may 
reveal, in our opinion, a normalization of aerobic metabolism with the stimulation of 
TCA cycle and oxidative phosphorylation to obtain energy more efficiently. Given the 
multiple metabolic pathways involving citrate (83), the overexpression of citrate 
synthase might represent a change of substrate for respiration, like lipids of other 
anapleurotic intermediates over carbohydrate substrates. 
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CONCLUDING REMARKS 
 
In conclusion the present study presents a paradoxical relationship between 
obesity and cancer. In a first view, conditioned medium (adipokines-enriched medium) 
may present a protective effect against glioma, since STI1, hnRNPs and PGK1 that are 
generally overexpressed in several types of cancer are underexpressed. Similarly, both 
carbonic anhydrase and aldose reductase that play an important role in cell physiology, 
inflammation and cancer metabolism are even suppressed in glioma cells that grown 
under adipokines-enriched environment. However this view may not be completely 
unexpected. A couple years ago, a team led by Steven Lehrer hypothesize that obesity 
might protect against benign brain tumors based on several epidemiological studies on 
the USA (88). They found that there was a significant inverse correlation between 
percent obesity versus percent benign brain tumors in 19 USA states (r = 0.666, p = 
0.002).  
Contrariwise, RFC1, KIF5C, ANXA2, N-RAP and RACK1 that are generally 
involved in the matrix remodeling, proliferation, migration, invasion of cancer cells are 
overexpressed in GL261 cell in the presence of the adipokines-enriched medium.  
Also the presence of citrate synthase only in glioma cells cultured under 
conditioned medium and the decreased expression of PGK1 supports the idea that under 
an obesity environment, glioma cells may reshuffle their metabolic patterns towards 
increased lipid consumption for aerobic ATP production over glucose and other simple 
sugars.  
Conditioned medium may presents both anticarcinogenic proteins and 
procarcinogenic proteins. 
RFC1, Aldose reductase and PGK1 reveal protective function in cancer 
initiation, although in an advanced stage they seem to be involved in its progression. 
PGK1 and carbonic anhydrase look like to sensitize tumoral cells to therapeutic. KIF5C, 
ANXA2, RACK1 and N-RAP are important in tumor progression and invasion of 
cancer cells. 
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It is clear that additional work will be required before complete understanding of 
the implication of obesity in malignant brain tumors biology. Meanwhile, the present 
work presents an interesting in vitro model for the study of glioma biology under a 
“obesity” environment, that can be explored for the understanding of cancer cells 
biology, for the search of biomarkers, prognostic markers and therapeutic approaches.   
 
 
 
 
 
 
Figure 10 – Interpretive model for the mechanism proposed that conditioned medium may 
presents both anticarcinogenic proteins and procarcinogenic proteins. 
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